ArticleMolecular metabolism2017
Lorcaserin improves glycemic control via a melanocortin neurocircuit.
Article in Molecular metabolism, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 61 citations in OpenAlex.
- Defining Predictors of Weight Loss Response to Lorcaserin.The Journal of clinical endocrinology and metabolism · 2023Trial
- Brain-Derived GLP-1-Understanding the Physiological Function and Anti-obesity Potential of Preproglucagon Neurons.Endocrinology · 2025Review
- G proteins of the GScience advances · 2025Article
- Therapeutic Strategies Against Metabolic Imbalance in a Male Mouse Model With 5-HT2CR Loss-of-Function.Endocrinology · 2024Article
- Article
- Unraveling the serotonin saga: from discovery to weight regulation and beyond - a comprehensive scientific review.Cell & bioscience · 2023Review
- New Insight into Selective Serotonin Receptor Agonists in the Central Nervous System, Studied with WAY163909 in Obese and Diabetic Wistar Rats.Brain sciences · 2023Article
- 5-HTNutrients · 2023Review
- The Regulatory Role of the Central and Peripheral Serotonin Network on Feeding Signals in Metabolic Diseases.International journal of molecular sciences · 2022Review
- Chronic Treatment With Psilocybin Decreases Changes in Body Weight in a Rodent Model of Obesity.Frontiers in psychiatry · 2022Article
- The serotonergic system dysfunction in diabetes mellitus.Frontiers in cellular neuroscience · 2022Review
- Effects of the POMC System on Glucose Homeostasis and Potential Therapeutic Targets for Obesity and Diabetes.Diabetes, metabolic syndrome and obesity : targets and therapy · 2022Review
- PERK in POMC neurons connects celastrol with metabolism.JCI insight · 2021Article
- Barbadin Potentiates Long-Term Effects of Lorcaserin on POMC Neurons and Weight Loss.The Journal of neuroscience : the official journal of the Society for Neuroscience · 2021Article
- Rap1 in the VMH regulates glucose homeostasis.JCI insight · 2021Article
- Role of serotonin in body weight, insulin secretion and glycaemic control.Journal of neuroendocrinology · 2021Review
- Central 5-HTR2C in the Control of Metabolic Homeostasis.Frontiers in endocrinology · 2021Review
- Lorcaserin Inhibit Glucose-Stimulated Insulin Secretion and Calcium Influx in Murine Pancreatic Islets.Frontiers in pharmacology · 2021Article
- Higher HbA1c levels associate with lower hippocampal serotonin transporter availability in non-diabetic adults with obesity.Scientific reports · 2020Article
- The Role of Anti-Obesity Medication in Prevention of Diabetes and Its Complications.Journal of obesity & metabolic syndrome · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors at 4 institutions in 3 countries.
Funding
Abstract
objectiveThe increasing prevalence of type 2 diabetes (T2D) and associated morbidity and mortality emphasizes the need for a more complete understanding of the mechanisms mediating glucose homeostasis to accelerate the identification of new medications. Recent reports indicate that the obesity medication lorcaserin, a 5-hydroxytryptamine (5-HT, serotonin) 2C receptor (5-HT
methodsMurine models of common and genetic T2D were utilized to probe the direct effect of lorcaserin on glycemic control.
resultsLorcaserin dose-dependently improves glycemic control in mouse models of T2D in the absence of reductions in food intake or body weight. Examining the mechanism of this effect, we reveal a necessary and sufficient neurochemical mediator of lorcaserin's glucoregulatory effects, brain pro-opiomelanocortin (POMC) peptides. To clarify further lorcaserin's therapeutic brain circuit, we examined the receptor target of POMC peptides. We demonstrate that lorcaserin requires functional melanocortin4 receptors on cholinergic preganglionic neurons (MC4R
conclusionsThese data suggest that lorcaserin's action within the brain represents a mechanistically novel treatment for T2D: findings of significance to a prevalent global disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.